Fmr LLC grew its stake in GRIFOLS S A/S (NASDAQ:GRFS) by 92.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,763,759 shares of the biotechnology company’s stock after buying an additional 6,600,205 shares during the period. Fmr LLC owned approximately 2.02% of GRIFOLS S A/S worth $294,132,000 as of its most recent SEC filing.
Other large investors also recently made changes to their positions in the company. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new stake in shares of GRIFOLS S A/S in the second quarter worth about $6,482,000. Tibra Equities Europe Ltd acquired a new stake in shares of GRIFOLS S A/S in the second quarter worth about $2,047,000. Citadel Advisors LLC acquired a new stake in shares of GRIFOLS S A/S in the second quarter worth about $795,000. Van ECK Associates Corp lifted its position in shares of GRIFOLS S A/S by 15.4% in the second quarter. Van ECK Associates Corp now owns 576,179 shares of the biotechnology company’s stock worth $12,388,000 after buying an additional 77,105 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of GRIFOLS S A/S by 24.3% in the second quarter. Northern Trust Corp now owns 516,070 shares of the biotechnology company’s stock worth $11,096,000 after buying an additional 100,769 shares during the last quarter. 20.17% of the stock is owned by institutional investors.
NASDAQ GRFS opened at $19.72 on Monday. GRIFOLS S A/S has a twelve month low of $17.47 and a twelve month high of $25.18. The company has a quick ratio of 1.07, a current ratio of 2.78 and a debt-to-equity ratio of 1.47. The stock has a market cap of $13.47 billion, a P/E ratio of 16.43, a price-to-earnings-growth ratio of 1.42 and a beta of 1.13.
The firm also recently disclosed a special dividend, which will be paid on Tuesday, December 11th. Investors of record on Monday, December 3rd will be given a dividend of $0.2283 per share. This represents a dividend yield of 2.25%. The ex-dividend date of this dividend is Friday, November 30th. This is a boost from GRIFOLS S A/S’s previous special dividend of $0.01. GRIFOLS S A/S’s payout ratio is currently 31.82%.
GRFS has been the subject of a number of analyst reports. Berenberg Bank raised GRIFOLS S A/S from a “hold” rating to a “buy” rating in a research report on Thursday, October 11th. Zacks Investment Research raised GRIFOLS S A/S from a “sell” rating to a “hold” rating in a research report on Tuesday, November 13th. Santander raised GRIFOLS S A/S from an “underperform” rating to a “hold” rating in a research report on Tuesday, October 30th. BidaskClub raised GRIFOLS S A/S from a “sell” rating to a “hold” rating in a research report on Tuesday, October 30th. Finally, UBS Group cut GRIFOLS S A/S from a “neutral” rating to a “sell” rating in a research report on Wednesday, October 3rd. Three analysts have rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $21.50.
GRIFOLS S A/S Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.
Featured Story: Bond
Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GRIFOLS S A/S (NASDAQ:GRFS).
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.